In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone
Related Experiment Videos
Abstract:
The antibacterial activity of N-formimidoyl thienamycin was compared with those of cefotaxime, cefoperazone, and piperacillin against 536 clinical aerobic isolates.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.
The Journal of infectious diseases·1996
Pharmacokinetic interactions of azithromycin and ethambutol with or without SPR720 in healthy participants.
Antimicrobial agents and chemotherapy·2026
Does pre-treatment with doxycycline improve the efficacy of combination minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium infections?
Antimicrobial agents and chemotherapy·2026
DNA methyltransferase HP1208 antagonizes Fur-mediated repression of GlmU to modulate β-lactam susceptibility in Helicobacter pylori.
Antimicrobial agents and chemotherapy·2026
In vitro and in vivo activity of OSUAB-0284, a preclinical candidate for Staphylococcus aureus infections.
Antimicrobial agents and chemotherapy·2026
Activity of oral β-lactams, tebipenem and ceftibuten, combined with novel oral β-lactamase inhibitors against broad-spectrum β-lactamase-producing Escherichia coli.
Antimicrobial agents and chemotherapy·2026
Rectal colonization with multidrug-resistant organisms in adult acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective, longitudinal, single-center study.
Frontiers in cellular and infection microbiology·2026
Virulence determinants in multidrug-resistant Acinetobacter baumannii: comparative phenotypic and genomic analysis of clinical and patient-environmental isolates.
Frontiers in cellular and infection microbiology·2026
Co-occurrence and genetic contexts of NDM-1, KPC-2, IMP-1, and AFM-1 carbapenemase genes in a critically ill patient.
Frontiers in cellular and infection microbiology·2026
Designing durable anti-tuberculosis regimens: physiological targeting, resistance fitness landscapes, and treatment optimization.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026